REVERSE SWITCHING TO ORIGINATOR INFLIXIMAB MAY BE CONSIDERED IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES EXPERIENCING NEW SIDE EFFECTS OR LOSS OF RESPONSE AFTER SWITCHING TO A CT-P13 BIOSIMILAR

Conference
UEG Week 2019


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing